Novo Nordisk Phase II Data Validate Triple-Agonist Metabolic Targeting Approach

Topline results from a Phase II clinical trial conducted in China suggest that UBT251, an investigational triple receptor agonist, may further expand the therapeutic potential of multi-hormone metabolic targeting approaches for obesity and related cardiometabolic disease. Jointly developed by Novo Nordisk and The United Bio-Technology (Hengqin) (United Biotechnology), a wholly owned subsidiary of The United Laboratories International Holdings Limited (TUL), UBT251 is a long-acting synthetic peptide.¹

The therapeutic is designed to activate receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. This approach extends beyond established incretin therapies by incorporating glucagon receptor signaling intended to influence energy expenditure alongside appetite regulation, according to Novo Nordisk.

In the randomized, double-blind, placebo-controlled Phase II study, which involved Chinese adults who were overweight or had obesity, once-weekly administration of UBT251 produced a statistically significant mean body-weight reduction of up to 19.7% after 24 weeks of treatment, compared with 2.0% observed in the placebo arm.¹

Participants entered the trial with a baseline mean body weight of 92.2 kg and mean body mass index of 33.1 kg/m². Across evaluated dose levels of 2 mg, 4 mg, and 6 mg, UBT251 demonstrated consistent improvements across multiple cardiometabolic secondary endpoints, including waist circumference, blood glucose, blood pressure, and lipid parameters.¹

How does triple agonist biology reshape metabolic drug development?

Next-generation obesity therapies increasingly aim to replicate coordinated endocrine signaling rather than targeting single metabolic pathways. By simultaneously activating GLP-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors, triple agonists seek to balance appetite suppression, insulin sensitivity, and energy expenditure mechanisms.²

This strategy builds on clinical validation achieved by earlier incretin-based therapies while attempting to enhance the magnitude and durability of weight reduction outcomes. The addition of glucagon receptor activity represents a differentiating mechanism intended to increase metabolic rate, potentially addressing limitations associated with weight-loss plateaus observed in some incretin regimens.³

Safety findings from the study, which was conducted by United Biotechnology, indicated that UBT251 was generally well tolerated, with adverse events primarily gastrointestinal in nature. Most events were mild to moderate and diminished over time, consistent with established incretin-class therapies.

“The success of the [Phase II] clinical trial of UBT251 in China represents another significant milestone in TUL’s innovation-driven development,” said Tsoi Hoi Shan, chairman of TUL, in a company press release.¹ “We will continue to focus on chronic diseases, including endocrine and metabolic disorders, accelerate the further development of UBT251, and strive to bring more high-quality treatment options to patients worldwide at the earliest opportunity.”

What do regional trials signal for global obesity therapy competition?

The collaboration structure between Novo Nordisk and United Biotechnology reflects an increasingly regionalized development model in metabolic disease drug development. United Biotechnology retains development rights across mainland China, Hong Kong, Macau, and Taiwan, while Novo Nordisk holds global commercialization rights outside those territories.

Following these Phase II findings, United Biotechnology plans to initiate a Phase III trial in Chinese patients with overweight or obesity. Novo Nordisk has independently initiated a global Phase Ib/IIa study evaluating pharmacokinetics, pharmacodynamics, safety, and tolerability across approximately 330 participants, with topline results expected in 2027. A separate Phase II trial in type 2 diabetes is anticipated to begin in the second half of 2026, according to the companies.¹

“We are very encouraged by these data from the trial in China, which demonstrate the potential of UBT251 and its differentiated clinical profile and safety and tolerability profile,” said Martin Holst Lange, executive vice president and chief scientific officer, Novo Nordisk, stated in the release.¹ “We look forward to reporting data from a global trial with UBT251 conducted by Novo Nordisk next year.”

The emerging dataset collectively positions triple agonist candidates within a rapidly intensifying obesity therapeutics landscape, in which differentiation increasingly depends on achieving greater metabolic efficacy while maintaining tolerability suitable for chronic administration. As multi-agonist peptide engineering advances, clinical outcomes from agents such as UBT251 may help define the next competitive phase of incretin-based drug development.

References

1. Novo Nordisk. Novo Nordisk: Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in Phase 2 trial in China. Press Release. Feb. 24, 2026.
2. Abdrabou Abouelmagd A, Abdelrehim AM, Bashir MN, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Proc (Bayl Univ Med Cent). 2025;38(3):291-303. doi: 10.1080/08998280.2025.2456441
3. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat. Med. 2024;30:2037-2048. doi: 10.1038/s41591-024-03018-2